SEARCH:   Advanced

Blood, 1 November 2007, Vol. 110, No. 9, pp. 3463-3471. Prepublished online as a Blood First Edition Paper on July 30, 2007; DOI 10.1182/blood-2006-10-054080. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-10-054080v1 110/9/3463    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tichelli, A. Articles by Gratwohl, A. Search for Related Content PubMed PubMed Citation Articles by Tichelli, A. Articles by Gratwohl, A. Related Collections Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation André Tichelli1, Christoph Bucher1, Alicia Rovó1, Georg Stussi1, Martin Stern1, Michael Paulussen2, Jörg Halter1, Sandrine Meyer-Monard1, Dominik Heim1, Dimitrios A. Tsakiris1, Barbara Biedermann3, Jakob R. Passweg1, and Alois Gratwohl1 1 Division of Hematology, University Hospital, Basel; 2 University Children's Hospital (UKBB), Pediatric Hematology/Oncology, Basel; 3 Department of Research, University Hospital, Basel, Switzerland We assessed incidence and risk factors of cardiovascular events in 265 patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT) between 1980 and 2000 and who survived at least 2 years. Results were compared with a cohort of 145 patients treated during the same period with autologous HSCT. The median age of patients with allogeneic HSCT at last follow-up was 39 years, and median follow-up was 9 years. Eighteen (6.8%) patients after allogeneic and 3 (2.1%) patients after autologous HSCT experienced an arterial event. The cumulative incidence of first arterial event after allogeneic HSCT was 22.1% (95% CI, 12.0-40.9) at 25 years. The cumulative incidence 15 years after allogeneic HSCT was 7.5% as compared with 2.3% after autologous HSCT. Adjusting for age, risk of an arterial event was significantly higher after allogeneic HSCT (RR 6.92; P =.009). In multivariate analysis, allogeneic HSCT (RR: 14.5; P =.003), and at least 2 of 4 cardiovascular risk factors (hypertension, dyslipidemia, diabetes, obesity) (RR: 12.4; P =.02) were associated with a higher incidence of arterial events after HSCT. Thus, long-term survivors after allogeneic HSCT are at high risk for premature arterial vascular disease. HSCT might favor the emergence of established risk factors, such as hypertension, diabetes, and dyslipidemia. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Cardiovascular Disease Following Stem-Cell Transplantation Journal Watch Oncology and Hematology, November 20, 2007; 2007(1120): 2 - 2. [Full Text]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020